Kendrick Yim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kendrick Yim has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Ithaar H. Derweesh
Department of Urology, Rush University Medical Center, Chicago, IL 60612, USA
6 shared publications Zachary A. Hamilton
UC San Diego School of Medicine, La Jolla, CA
5 shared publicationsBrian R. Lane
Spectrum Health, Grand Rapids, MI
4 shared publicationsSumi Dey
Spectrum Health, Grand Rapids, MI
4 shared publicationsAdam S. Kibel
Division of Urology
3 shared publicationsAhmet Bindayi
Department of Urology, University of California, San Diego, School of Medicine, La Jolla, CA
3 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 4 (9)
Clinical and Genomic Profiling of Early-Onset Bladder Cancer Identifies Key Alterations and Therapeutic Targets
Purpose: Younger patients with bladder cancer have fewer environmental exposures or risk factors, suggesting that the molecular pathways implicated in early-onset disease differ from older patients. Dissecting the genomic profiles of early-onset tumors may inform targeted treatment strategies for young patients. We compared the frequency of somatic mutations in early-onset bladder cancer, defined as a diagnosis before the age of 55 years, which encompasses the youngest patients in approximately 1 in 10 diagnoses based on national registries. Material and methods: We assessed 2 institutional cohorts: the Mass General Brigham Young Cystectomy Cohort (MGB-YCC, n = 134 patients) from 2008 to 2023 and the Memorial Sloan Kettering-IMPACT bladder cancer cohort (MSK-IMPACT, n = 1271 including n = 207 cystectomy and n = 811 transurethral resection (TUR) specimens) from 2014 to 2021. Clinical outcomes were compared with patients undergoing cystectomy in the National Surgical Quality Improvement Program (NSQIP, n = 10,848). Results: MGB-YCC and MSK-IMPACT cohorts were predominantly male (> 75%), and younger patients had lower rates of smoking history or muscle-invasive disease. MGB-YCC demonstrated more patients with continent diversions (51.5% vs 14.9%) than the older population in NSQIP, although complication rates were similar. Genomic characterization of MGB-YCC demonstrated enrichment in younger patients of TP53 (65% overall, 83% < 50-year- old, P = .045) and KMT2D mutations almost exclusively in the youngest patients (35% overall, 83% < 45-years-old, P = .008). MSK-IMPACT revealed a significant increase in FGFR3 mutations in younger patients in both cystectomy (33% vs 13%, P = .014) and TUR (45% vs 27%, P < .001). Conclusions: Our results indicate that early-onset bladder cancer is a distinct patient population that has disease driven by specific somatic mutations, some of which represent therapeutic targets. This suggests potential benefits of genomic tumor profiling in guiding personalized treatment.
- 1 September 2026
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 4 (9)
Open AccessClinical and Genomic Profiling of Early-Onset Bladder Cancer Identifies Key Alterations and Therapeutic Targets
Purpose: Younger patients with bladder cancer have fewer environmental exposures or risk factors, suggesting that the molecular pathways implicated in early-onset disease differ from older patients. Dissecting the genomic profiles of early-onset tumors may inform targeted treatment strategies for young patients. We compared the frequency of somatic mutations in early-onset bladder cancer, defined as a diagnosis before the age of 55 years, which encompasses the youngest patients in approximately 1 in 10 diagnoses based on national registries. Material and methods: We assessed 2 institutional cohorts: the Mass General Brigham Young Cystectomy Cohort (MGB-YCC, n = 134 patients) from 2008 to 2023 and the Memorial Sloan Kettering-IMPACT bladder cancer cohort (MSK-IMPACT, n = 1271 including n = 207 cystectomy and n = 811 transurethral resection (TUR) specimens) from 2014 to 2021. Clinical outcomes were compared with patients undergoing cystectomy in the National Surgical Quality Improvement Program (NSQIP, n = 10,848). Results: MGB-YCC and MSK-IMPACT cohorts were predominantly male (> 75%), and younger patients had lower rates of smoking history or muscle-invasive disease. MGB-YCC demonstrated more patients with continent diversions (51.5% vs 14.9%) than the older population in NSQIP, although complication rates were similar. Genomic characterization of MGB-YCC demonstrated enrichment in younger patients of TP53 (65% overall, 83% < 50-year- old, P = .045) and KMT2D mutations almost exclusively in the youngest patients (35% overall, 83% < 45-years-old, P = .008). MSK-IMPACT revealed a significant increase in FGFR3 mutations in younger patients in both cystectomy (33% vs 13%, P = .014) and TUR (45% vs 27%, P < .001). Conclusions: Our results indicate that early-onset bladder cancer is a distinct patient population that has disease driven by specific somatic mutations, some of which represent therapeutic targets. This suggests potential benefits of genomic tumor profiling in guiding personalized treatment.
- Open Access
- 29 February 2024
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 2 (3)
Contemporary Perioperative Outcomes of Open Retroperitoneal Lymph Node Dissection for Testicular Cancer
Purpose: Retroperitoneal lymph node dissection (RPLND) is an essential component of multimodal treatment of testicular cancer. The latest data on the perioperative outcomes of RPLNDs performed using the open approach (O-RPLND) dates back over a decade. We report our contemporary institutional perioperative outcomes with O-RPLND. Materials and Methods: We retrospectively identified all patients who underwent O-RPLND between 2013 and 2022 across our institution. Clinical and demographic data were reviewed and recorded. Descriptive statistics and univariate analysis were performed with patients stratified according to primary RPLND and post-chemotherapy RPLND (PC-RPLND). Results: Our cohort included a total of 144 men. Seventy-seven percent of all cases were PC-RPLND. The PC-RPLND cohort showed higher preoperative clinical stages (81% vs 26% above cN1, P < .001; 41% vs 1% Stage 3, P < .001). PC-RPLND pathologies were more likely to be teratoma and necrosis or fibrosis (43% vs 6% and 39% vs 33%, P < .001). Estimated blood loss was significantly higher in the PC-RPLND group (291 vs 125 cc, P = .004). Operative time was longer for PC-RPLND (242 vs 196 minutes, P = .011). Length of stay and 30-day readmission rate were not significantly different between groups and averaged 4.3 days and 12%, respectively. Our most common complication was ileus (5%), followed by chyle leak (3%). Conclusions: While PC-RPLND becomes prominent for treating advanced testicular cancer, our recent data suggest positive perioperative results with O-RPLND. With long-term outcome data needed to appropriately select patients for robotic RPLND, O-RPLND in experienced hands continues to improve its outcome and remains the standard approach in the modern era.
- 29 February 2024
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 2 (3)
Open AccessContemporary Perioperative Outcomes of Open Retroperitoneal Lymph Node Dissection for Testicular Cancer
Purpose: Retroperitoneal lymph node dissection (RPLND) is an essential component of multimodal treatment of testicular cancer. The latest data on the perioperative outcomes of RPLNDs performed using the open approach (O-RPLND) dates back over a decade. We report our contemporary institutional perioperative outcomes with O-RPLND. Materials and Methods: We retrospectively identified all patients who underwent O-RPLND between 2013 and 2022 across our institution. Clinical and demographic data were reviewed and recorded. Descriptive statistics and univariate analysis were performed with patients stratified according to primary RPLND and post-chemotherapy RPLND (PC-RPLND). Results: Our cohort included a total of 144 men. Seventy-seven percent of all cases were PC-RPLND. The PC-RPLND cohort showed higher preoperative clinical stages (81% vs 26% above cN1, P < .001; 41% vs 1% Stage 3, P < .001). PC-RPLND pathologies were more likely to be teratoma and necrosis or fibrosis (43% vs 6% and 39% vs 33%, P < .001). Estimated blood loss was significantly higher in the PC-RPLND group (291 vs 125 cc, P = .004). Operative time was longer for PC-RPLND (242 vs 196 minutes, P = .011). Length of stay and 30-day readmission rate were not significantly different between groups and averaged 4.3 days and 12%, respectively. Our most common complication was ileus (5%), followed by chyle leak (3%). Conclusions: While PC-RPLND becomes prominent for treating advanced testicular cancer, our recent data suggest positive perioperative results with O-RPLND. With long-term outcome data needed to appropriately select patients for robotic RPLND, O-RPLND in experienced hands continues to improve its outcome and remains the standard approach in the modern era.
- 1 October 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 210 (4) , 630-638
Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial
We studied whether adding percent free prostate-specific antigen (%fPSA) to total PSA improves prediction of clinically significant prostate cancer (csPCa) and fatal PCa. 6727 men within the intervention arm of the Prostate, Lung, Colorectal and Ovarian Trial had baseline %fPSA. Of this cohort, 475 had csPCa and 98 had fatal PCa. Cumulative incidence and Cox analyses were conducted to evaluate the association between %fPSA/PSA and csPCa/fatal PCa. Harrell's concordance-index (C-index) evaluated predictive ability. Kaplan-Meier analysis assessed survival. Median follow-up was 19.7 years, median baseline PSA was 1.19 ng/mL, median %fPSA was 18%. Cumulative incidence of fatal PCa for men with baseline PSA≥2 ng/mL and %fPSA ≤10 was 3.2% and 6.1% at 15 and 25 years, compared to 0.03% and 1.1% for men with %fPSA >25%. In younger men (55-64 yr) with baseline PSA 2-10 ng/mL, C-index improved from 0.56 to 0.60 for csPCa and from 0.53 to 0.64 for fatal PCa with addition of %fPSA. In older men (65-74 yr), C-index improved for csPCa from 0.60 to 0.66, while no improvement in fatal PCa. Adjusting for age, digital rectal exam, family history of PCa, and total PSA, %fPSA was associated with csPCa (HR 1.05, P < .001) per 1% decrease. %fPSA improved prediction of csPCa and fatal PCA for all race groups. In a large US screening trial, the addition of %fPSA to total PSA in men with baseline PSA ≥2 ng/mL improved prediction of csPCa and fatal PCa. Free PSA should be used to risk-stratify screening and decrease unnecessary prostate biopsies.
- 1 October 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 210 (4) , 630-638
Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial
We studied whether adding percent free prostate-specific antigen (%fPSA) to total PSA improves prediction of clinically significant prostate cancer (csPCa) and fatal PCa. 6727 men within the intervention arm of the Prostate, Lung, Colorectal and Ovarian Trial had baseline %fPSA. Of this cohort, 475 had csPCa and 98 had fatal PCa. Cumulative incidence and Cox analyses were conducted to evaluate the association between %fPSA/PSA and csPCa/fatal PCa. Harrell's concordance-index (C-index) evaluated predictive ability. Kaplan-Meier analysis assessed survival. Median follow-up was 19.7 years, median baseline PSA was 1.19 ng/mL, median %fPSA was 18%. Cumulative incidence of fatal PCa for men with baseline PSA≥2 ng/mL and %fPSA ≤10 was 3.2% and 6.1% at 15 and 25 years, compared to 0.03% and 1.1% for men with %fPSA >25%. In younger men (55-64 yr) with baseline PSA 2-10 ng/mL, C-index improved from 0.56 to 0.60 for csPCa and from 0.53 to 0.64 for fatal PCa with addition of %fPSA. In older men (65-74 yr), C-index improved for csPCa from 0.60 to 0.66, while no improvement in fatal PCa. Adjusting for age, digital rectal exam, family history of PCa, and total PSA, %fPSA was associated with csPCa (HR 1.05, P < .001) per 1% decrease. %fPSA improved prediction of csPCa and fatal PCA for all race groups. In a large US screening trial, the addition of %fPSA to total PSA in men with baseline PSA ≥2 ng/mL improved prediction of csPCa and fatal PCa. Free PSA should be used to risk-stratify screening and decrease unnecessary prostate biopsies.
- 9 September 2023
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 41 (11) , 458.e1-458.e7
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy
- 9 September 2023
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 41 (11) , 458.e1-458.e7
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy
- 22 July 2023
- Published by Elsevier in European Urology Oncology
- Vol. 7 (1) , 147-150
Stereotactic Magnetic Resonance–guided Adaptive Radiation Therapy for Localized Kidney Cancer: Early Outcomes from a Prospective Phase 1 Trial and Supplemental Cohort
- 22 July 2023
- Published by Elsevier in European Urology Oncology
- Vol. 7 (1) , 147-150
Stereotactic Magnetic Resonance–guided Adaptive Radiation Therapy for Localized Kidney Cancer: Early Outcomes from a Prospective Phase 1 Trial and Supplemental Cohort
- 19 July 2023
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 21 (6) , 694-702
Outcomes of Consolidative Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter Analysis
- 19 July 2023
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 21 (6) , 694-702
Outcomes of Consolidative Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter Analysis
- 1 June 2019
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 17 (3) , e505-e512
Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis
- 1 June 2019
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 17 (3) , e505-e512
Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis
- 1 February 2019
- Published by Springer Nature in World Journal of Urology
- Vol. 37 (11) , 2429-2437
Should partial nephrectomy be considered “elective” in patients with stage 2 chronic kidney disease? A comparative analysis of functional and survival outcomes after radical and partial nephrectomy
To compare renal function and survival outcomes in patients with baseline chronic kidney disease (CKD) stage 2 undergoing partial (PN) or radical nephrectomy (RN), as nephron-sparing surgery is considered to be elective in this group.
- 1 February 2019
- Published by Springer Nature in World Journal of Urology
- Vol. 37 (11) , 2429-2437
Should partial nephrectomy be considered “elective” in patients with stage 2 chronic kidney disease? A comparative analysis of functional and survival outcomes after radical and partial nephrectomy
To compare renal function and survival outcomes in patients with baseline chronic kidney disease (CKD) stage 2 undergoing partial (PN) or radical nephrectomy (RN), as nephron-sparing surgery is considered to be elective in this group.
- Open Access
- 3 May 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-13
HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
Heat shock factor 1 (HSF1) initiates a broad transcriptional response to proteotoxic stress while also mediating a cancer-specific transcriptional program. HSF1 is thought to be regulated by molecular chaperones, including Heat Shock Protein 90 (HSP90). HSP90 is proposed to sequester HSF1 in unstressed cells, but visualization of this interaction in vivo requires protein crosslinking. In this report, we show that HSP90 binding to HSF1 depends on HSP90 conformation and is only readily visualized for the ATP-dependent, N-domain dimerized chaperone, a conformation only rarely sampled by mammalian HSP90. We have used this mutationally fixed conformation to map HSP90 binding sites on HSF1. Further, we show that ATP-competitive, N-domain targeted HSP90 inhibitors disrupt this interaction, resulting in the increased duration of HSF1 occupancy of the hsp70 promoter and significant prolongation of both the constitutive and heat-induced HSF1 transcriptional activity. While our data do not support a role for HSP90 in sequestering HSF1 monomers to suppress HSF1 transcriptional activity, our findings do identify a noncanonical role for HSP90 in providing dynamic modulation of HSF1 activity by participating in removal of HSF1 trimers from heat shock elements in DNA, thus terminating the heat shock response.
- 3 May 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-13
Open AccessHSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
Heat shock factor 1 (HSF1) initiates a broad transcriptional response to proteotoxic stress while also mediating a cancer-specific transcriptional program. HSF1 is thought to be regulated by molecular chaperones, including Heat Shock Protein 90 (HSP90). HSP90 is proposed to sequester HSF1 in unstressed cells, but visualization of this interaction in vivo requires protein crosslinking. In this report, we show that HSP90 binding to HSF1 depends on HSP90 conformation and is only readily visualized for the ATP-dependent, N-domain dimerized chaperone, a conformation only rarely sampled by mammalian HSP90. We have used this mutationally fixed conformation to map HSP90 binding sites on HSF1. Further, we show that ATP-competitive, N-domain targeted HSP90 inhibitors disrupt this interaction, resulting in the increased duration of HSF1 occupancy of the hsp70 promoter and significant prolongation of both the constitutive and heat-induced HSF1 transcriptional activity. While our data do not support a role for HSP90 in sequestering HSF1 monomers to suppress HSF1 transcriptional activity, our findings do identify a noncanonical role for HSP90 in providing dynamic modulation of HSF1 activity by participating in removal of HSF1 trimers from heat shock elements in DNA, thus terminating the heat shock response.
- 1 April 2018
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 16 (2) , e289-e295
Renal Functional Outcome of Partial Nephrectomy for Complex R.E.N.A.L. Score Tumors With or Without Neoadjuvant Sunitinib: A Multicenter Analysis
- 1 April 2018
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 16 (2) , e289-e295
Renal Functional Outcome of Partial Nephrectomy for Complex R.E.N.A.L. Score Tumors With or Without Neoadjuvant Sunitinib: A Multicenter Analysis